Helen Louise Collins, CHIEF MEDICAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 5,000 shares at $50.05 ($263K) on 2026-07-17, disclosed to the SEC on 2026-07-21.
Scheduled sale ($263k) by CHIEF MEDICAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.05 | 231 | $12K | 4.4% |
| 2 | $51.55 | 459 | $24K | 9.0% |
| 3 | $52.39 | 2,063 | $108K | 41.0% |
| 4 | $53.42 | 2,184 | $117K | 44.3% |
| 5 | $53.92 | 63 | $3K | 1.3% |
| Total | $52.67 avg | 5,000 |
| $263K |
| 100% |
| Filing → |
| ELVN | SELL | 2026-06-22 | $219K | — | Filing → |
| ELVN | SELL | 2026-05-20 | $199K | — | Filing → |
| ELVN | SELL | 2026-04-21 | $238K | — | Filing → |